metaLead Therapeutics is to develop this peptide as a next-generation Pb poisoning treatment.
metaLead Therapeutics has raised $1.2M in total funding. The most recent round was Seed. The last funding was announced in May 2025.
metaLead Therapeutics's investors include BioInnovation Institute, Venture Kick, UZH Life Sciences Fund.
metaLead Therapeutics is headquartered in Zürich, Switzerland.
metaLead Therapeutics is to develop this peptide as a next-generation Pb poisoning treatment.
metaLead Therapeutics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"metaLead Therapeutics — Funding & Investors." VCBacked, May 6, 2025, https://www.vcbacked.co/company/metalead-therapeutics. Accessed September 29, 2026.
VCBacked. (2025). metaLead Therapeutics — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/metalead-therapeutics
{{cite web |title=metaLead Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/metalead-therapeutics |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated